Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20051480
Pöll F, et al. (2010) Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol 24, 436-46 20051480
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T353-p - SSTR2 (rat)
Modsite: DKsRLNEttEtQRtL SwissProt
Orthologous residues
SSTR2 (human): T353‑p, SSTR2 (mouse): T353‑p, SSTR2 (rat): T353‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  293 (epithelial), GH3 (epithelial), INS-1 (pancreatic), pancreas, pituitary gland
Cellular systems studied:  cell lines, tissue
Species studied:  human, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK3 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme
KINASE GRK2 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
octreotide increase
L779,976 increase
SST14 increase
phorbol_ester no change compared to control
siRNA SST14 inhibit treatment-induced increase GRK2 and GRK3 siRNA
phorbol_ester SST14 no effect upon treatment-induced increase
pasireotide SST14 inhibit treatment-induced increase
octreotide SST14 augment treatment-induced increase
BIM23627 SST14 inhibit treatment-induced increase
pasireotide no change compared to control

T354-p - SSTR2 (rat)
Modsite: KsRLNEttEtQRtLL SwissProt
Orthologous residues
SSTR2 (human): T354‑p, SSTR2 (mouse): T354‑p, SSTR2 (rat): T354‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  293 (epithelial), GH3 (epithelial), INS-1 (pancreatic), pancreas, pituitary gland
Cellular systems studied:  cell lines, tissue
Species studied:  human, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK2 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme
KINASE GRK3 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
octreotide increase
L779,976 increase
SST14 increase
phorbol_ester no change compared to control
siRNA SST14 inhibit treatment-induced increase GRK2 and GRK3 siRNA
phorbol_ester SST14 no effect upon treatment-induced increase
pasireotide SST14 inhibit treatment-induced increase
octreotide SST14 augment treatment-induced increase
BIM23627 SST14 inhibit treatment-induced increase
pasireotide no change compared to control

T356-p - SSTR2 (rat)
Modsite: RLNEttEtQRtLLNG SwissProt
Orthologous residues
SSTR2 (human): T356‑p, SSTR2 (mouse): T356‑p, SSTR2 (rat): T356‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  293 (epithelial), GH3 (epithelial), INS-1 (pancreatic), pancreas, pituitary gland
Cellular systems studied:  cell lines, tissue
Species studied:  human, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK3 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme
KINASE GRK2 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
octreotide increase
L779,976 increase
SST14 increase
phorbol_ester no change compared to control
siRNA SST14 inhibit treatment-induced increase GRK2 and GRK3 siRNA
phorbol_ester SST14 no effect upon treatment-induced increase
pasireotide SST14 inhibit treatment-induced increase
octreotide SST14 augment treatment-induced increase
BIM23627 SST14 inhibit treatment-induced increase
pasireotide no change compared to control
Downstream Regulation
Effect of modification (function):  receptor internalization, altered

T359-p - SSTR2 (rat)
Modsite: EttEtQRtLLNGDLQ SwissProt
Orthologous residues
SSTR2 (human): T359‑p, SSTR2 (mouse): T359‑p, SSTR2 (rat): T359‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  293 (epithelial), GH3 (epithelial), INS-1 (pancreatic), pancreas, pituitary gland
Cellular systems studied:  cell lines, tissue
Species studied:  human, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK3 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme
KINASE GRK2 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
octreotide increase
L779,976 increase
SST14 increase
phorbol_ester no change compared to control
siRNA SST14 inhibit treatment-induced increase GRK2 and GRK3 siRNA
phorbol_ester SST14 no effect upon treatment-induced increase
pasireotide SST14 inhibit treatment-induced increase
octreotide SST14 augment treatment-induced increase
BIM23627 SST14 inhibit treatment-induced increase
pasireotide no change compared to control
Downstream Regulation
Effect of modification (function):  receptor internalization, altered